---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-031204"
form_type: "8-K"
ticker: "HCWB"
cik: "0001828673"
company_name: "HCW Biologics Inc."
filed_at: "2026-06-30T12:30:20+00:00"
generated_at: "2026-06-30T12:35:12.167435+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# HCW Biologics regains Nasdaq bid price compliance; will effect 1-for-6 reverse split

## Summary
- Nasdaq Panel confirmed compliance with Bid Price Rule; mandatory monitoring through June 17, 2027.
- Company to effect 1-for-6 reverse stock split on June 30, 2026 to maintain compliance.
- If non-compliant during monitoring, no additional cure period; may face delisting.
- Company now compliant with all Nasdaq continued listing rules.

## SEC filing metadata
- accession: 0001493152-26-031204
- form_type: 8-K
- ticker: HCWB
- cik: 0001828673
- company_name: HCW Biologics Inc.
- filed_at: 2026-06-30T12:30:20+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828673/000149315226031204/0001493152-26-031204-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828673/000149315226031204/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-031204
- JSON: https://secwatch.observer/filing/0001493152-26-031204.json
- Plain text: https://secwatch.observer/filing/0001493152-26-031204.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.